NASDAQ:RVPH Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free RVPH Stock Alerts $2.99 +0.01 (+0.34%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.94▼$3.0850-Day Range$2.76▼$4.3952-Week Range$2.67▼$9.25Volume115,227 shsAverage Volume177,639 shsMarket Capitalization$83.48 millionP/E RatioN/ADividend YieldN/APrice Target$16.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Reviva Pharmaceuticals alerts: Email Address Reviva Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside460.2% Upside$16.75 Price TargetShort InterestBearish4.41% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector484th out of 913 stocksPharmaceutical Preparations Industry212th out of 420 stocks 3.5 Analyst's Opinion Consensus RatingReviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageReviva Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.41% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently increased by 16.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVPH. Previous Next 2.9 News and Social Media Coverage News SentimentReviva Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Reviva Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest8 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows8 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.83% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to remain at ($0.93) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReviva Pharmaceuticals has a P/B Ratio of 14.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.Read More RVPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVPH Stock News HeadlinesApril 25, 2024 | finance.yahoo.comRVPH: Full Year 2023 ResultsApril 25, 2024 | businesswire.comRVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPHApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 25, 2024 | americanbankingnews.comHC Wainwright Research Analysts Lower Earnings Estimates for Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)April 24, 2024 | americanbankingnews.comQ1 2025 Earnings Forecast for Reviva Pharmaceuticals Holdings, Inc. Issued By HC Wainwright (NASDAQ:RVPH)April 23, 2024 | americanbankingnews.comReviva Pharmaceuticals' (RVPH) "Buy" Rating Reaffirmed at HC WainwrightApril 23, 2024 | americanbankingnews.comReviva Pharmaceuticals (NASDAQ:RVPH) and Bristol-Myers Squibb (NYSE:BMY) Financial AnalysisApril 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 17, 2024 | americanbankingnews.comReviva Pharmaceuticals (NASDAQ:RVPH) Given Speculative Buy Rating at BenchmarkApril 15, 2024 | msn.comRVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER DataApril 15, 2024 | investorplace.comRVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023April 15, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business HighlightsApril 15, 2024 | globenewswire.comReviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | globenewswire.comReviva Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 28, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 28, 2024 | globenewswire.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 27, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual MeetingMarch 25, 2024 | markets.businessinsider.comOptimistic Buy Rating for Reviva Pharmaceuticals Based on Brilaroxazine’s Broad Therapeutic PromiseMarch 14, 2024 | finance.yahoo.comRVPH Mar 2024 3.000 putMarch 11, 2024 | globenewswire.comReviva to Present at the UBS Virtual CNS DayMarch 7, 2024 | globenewswire.comReviva to Present at the 36th Annual ROTH ConferenceMarch 3, 2024 | finance.yahoo.comRVPH Mar 2024 3.500 callFebruary 29, 2024 | finance.yahoo.comRVPH Jan 2026 5.500 callFebruary 27, 2024 | finance.yahoo.comRVPH Apr 2024 12.500 callFebruary 23, 2024 | ca.finance.yahoo.comRVPH Mar 2024 4.500 putSee More Headlines Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVPH CUSIPN/A CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$16.75 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+460.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,409.55% Return on Assets-291.73% Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book14.95Miscellaneous Outstanding Shares27,920,000Free Float19,032,000Market Cap$83.48 million OptionableOptionable Beta-0.02 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Laxminarayan Bhat Ph.D. (Age 59)Founder, CEO, President & Director Comp: $560kMr. Narayan Prabhu (Age 52)Chief Financial Officer Comp: $412.5kKey CompetitorsAssertioNASDAQ:ASRTAclaris TherapeuticsNASDAQ:ACRSEton PharmaceuticalsNASDAQ:ETONQ32 BioNASDAQ:QTTBChimerixNASDAQ:CMRXView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 62,600 shares on 2/15/2024Ownership: 0.000%Armistice Capital LLCBought 1,164,000 shares on 2/13/2024Ownership: 6.318%Simplex Trading LLCSold 600 shares on 2/2/2024Ownership: 0.000%Vontobel Holding Ltd.Bought 14,000 shares on 1/30/2024Ownership: 0.062%View All Institutional Transactions RVPH Stock Analysis - Frequently Asked Questions Should I buy or sell Reviva Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RVPH shares. View RVPH analyst ratings or view top-rated stocks. What is Reviva Pharmaceuticals' stock price target for 2024? 4 equities research analysts have issued 12 month price objectives for Reviva Pharmaceuticals' shares. Their RVPH share price targets range from $12.00 to $20.00. On average, they anticipate the company's stock price to reach $16.75 in the next twelve months. This suggests a possible upside of 460.2% from the stock's current price. View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts. How have RVPH shares performed in 2024? Reviva Pharmaceuticals' stock was trading at $5.15 at the beginning of the year. Since then, RVPH shares have decreased by 41.9% and is now trading at $2.99. View the best growth stocks for 2024 here. Are investors shorting Reviva Pharmaceuticals? Reviva Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,060,000 shares, an increase of 62.9% from the March 15th total of 650,700 shares. Based on an average daily volume of 331,800 shares, the short-interest ratio is presently 3.2 days. View Reviva Pharmaceuticals' Short Interest. When is Reviva Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RVPH earnings forecast. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) released its quarterly earnings data on Monday, April, 15th. The company reported ($0.35) earnings per share (EPS) for the quarter. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RVPH) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
